SynthesisCurrent rheumatology reports2021
Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?
Synthesis in Current rheumatology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Autoantibodies as potential prognostic factors for clinical outcomes related to COVID-19: a systematic review of inception prospective cohort studies with GRADE recommendations.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Pooled it
- Definition, Symptoms, Risk Factors, Epidemiology, and Autoimmunity of Long COVID.American journal of medicine open · 2026Article
- Effects of antiphospholipid antibodies in the severity and outcome of COVID-19.BMC infectious diseases · 2026Article
- The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.Biomedicines · 2025Article
- Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study.Frontiers in immunology · 2025Article
- Lupus Anticoagulant Detection under the Magnifying Glass.Journal of clinical medicine · 2023Review
- Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity.Biomedicines · 2023Article
- A Patient with Severe Fever with Thrombocytopenia Syndrome, Activated Partial Thromboplastin Time Prolongation, and Transient Antiphospholipid Antibodies.Internal medicine (Tokyo, Japan) · 2023Article
- The Effect of COVID-19 Severity, Associated Serum Autoantibodies and Time Interval after the Disease on the Outcomes of Fresh Oocyte ART Cycles in Non-Vaccinated Patients.Journal of clinical medicine · 2023Article
- A Post-Pandemic Enigma: The Cardiovascular Impact of Post-Acute Sequelae of SARS-CoV-2.Circulation research · 2023Review
- From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children.International journal of molecular sciences · 2023Review
- Anticardiolipin and anti-beta-2 glycoprotein I antibodies in patients with moderate or severe COVID-19.The American journal of the medical sciences · 2023Article
- COVID-19 and the antiphospholipid syndrome.Autoimmunity reviews · 2022Review
- Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies.International journal of molecular sciences · 2022Article
- COVID-19 and antiphospholipid antibodies.Best practice & research. Clinical haematology · 2022Review
- Prevalence and Clinical Significance of Antiphospholipid Antibodies in Hospitalized Patients With COVID-19 Infection.Cureus · 2022Article
- Vasculopathy in COVID-19.Blood · 2022Review
- Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.Journal of clinical medicine · 2022Review
- SARS- CoV-2 infection and oxidative stress in early-onset preeclampsia.Biochimica et biophysica acta. Molecular basis of disease · 2022Review
- Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012-2021).Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCOVID-19 patients have a procoagulant state with a high prevalence of thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) has been suggested by several reports. Here, we reviewed 48 studies investigating aPL in COVID-19 patients. RECENT
findingsPrevalence of Lupus Anticoagulant (LA) ranged from 35% to 92% in ICU patients. Anti-cardiolipin (aCL) IgG and IgM were found in up to 52% and up to 40% of patients respectively. Anti-β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.